Lancet Women's Health Papers Find No Clear Rise in Most Pregnancy Risks After GLP-1 Exposure, but Flag Early Pregnancy Loss and Evidence Gaps
The Lancet Obstetrics, Gynaecology & Women's Health published two papers on GLP-1 drugs in women on Tuesday, September 29, 2026. A systematic review, meta-analysis, and international consensus statement led by Sarah Dib pooled seven studies covering more than 43,000 exposed women with diabetes and found no clear link to congenital anomalies, preterm birth, stillbirth, or preeclampsia; early pregnancy loss, which counted miscarriages and terminations together, was 31% more common among exposed women in two studies, a result the authors said needs caution. A companion review led by Claire Meek of the Leicester Diabetes Research Centre said the drugs' global rollout has outpaced guidance for women and cited studies in which most long-term users fell short on vitamin D, iron, and other nutrients.